Lexaria Bioscience (LEXX) Return on Capital Employed (2018 - 2026)
Lexaria Bioscience (LEXX) posted Return on Capital Employed of 146.79% for Q2 2026, up 6.1% sequentially from 156.33% in Q1 2026, and up 3637.0% YoY from 3.93% in Q2 2025.
Lexaria Bioscience (LEXX) Return on Capital Employed (2018 - 2026) Analysis & Trends
Lexaria Bioscience has reported Return on Capital Employed for 9 years, with the latest figure at 146.79% in Q2 2026.
- Quarterly Return on Capital Employed rose 3637.0% year-over-year to 146.79% in Q2 2026, while the trailing twelve-month figure through May 2026 was 146.79% (up 3637.0% YoY) and the FY2025 annual result came in at 236.29%, down 11831.0% from the prior year.
- Return on Capital Employed advanced to 146.79% in Q2 2026 per LEXX's latest filing, from 156.33% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 5791.53% in Q1 2023 and troughed at 423.31% in Q3 2023.
- A 5-year average of 200.6% and a median of 162.8% in 2026 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed soared 585567 bps in 2023, then sank 597935 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 170.82% in 2022, then sank by 136 bps to 402.87% in 2023, then jumped by 80 bps to 80.87% in 2024, then plunged by 264 bps to 294.38% in 2025, then jumped by 50 bps to 146.79% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 146.79%, 156.33%, and 294.38% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | -146.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -146.79% |
| Feb 28, 2026 | -156.33% |
| Nov 30, 2025 | -294.38% |
| Aug 31, 2025 | -299.66% |
| May 31, 2025 | -183.16% |
| Feb 28, 2025 | -126.63% |
| Nov 30, 2024 | -80.87% |
| Aug 31, 2024 | -169.36% |
| May 31, 2024 | -169.27% |
| Feb 29, 2024 | -187.82% |
| Nov 30, 2023 | -402.87% |
| Aug 31, 2023 | -423.31% |
| May 31, 2023 | 845.75% |
| Feb 28, 2023 | 5,791.53% |
| Nov 30, 2022 | -170.82% |
| Aug 31, 2022 | -79.83% |
| May 31, 2022 | -71.24% |
| Feb 28, 2022 | -64.14% |
| Nov 30, 2021 | -56.87% |
| Aug 31, 2021 | -41.13% |